4//SEC Filing
Davis Andrew S. 4
Accession 0001593968-23-000739
CIK 0001397702other
Filed
May 2, 8:00 PM ET
Accepted
May 3, 6:39 PM ET
Size
25.1 KB
Accession
0001593968-23-000739
Insider Transaction Report
Form 4
Davis Andrew S.
EVP Global Sales & Marketing
Transactions
- Exercise/Conversion
Common Stock
2023-05-01$6.11/sh+482$2,945→ 116,165 total - Exercise/Conversion
Common Stock
2023-05-01$20.00/sh+474$9,480→ 116,639 total - Exercise/Conversion
Common Stock
2023-05-01$4.73/sh+2,584$12,222→ 119,223 total - Exercise/Conversion
Common Stock
2023-05-01$4.73/sh+3,213$15,197→ 122,436 total - Sale
Common Stock
2023-05-01$44.51/sh−482$21,455→ 121,954 total - Sale
Common Stock
2023-05-01$44.51/sh−474$21,099→ 121,480 total - Sale
Common Stock
2023-05-01$44.51/sh−2,584$115,020→ 118,896 total - Sale
Common Stock
2023-05-01$44.51/sh−3,213$143,019→ 115,683 total - Exercise/Conversion
Option (right to buy)
2023-05-01−3,213→ 44,238 totalExercise: $4.73From: 2017-09-01Exp: 2027-11-30→ Common Stock (3,213 underlying) - Exercise/Conversion
Option (right to buy)
2023-05-01−482→ 1,853 totalExercise: $6.11From: 2019-08-01Exp: 2028-09-13→ Common Stock (482 underlying) - Exercise/Conversion
Option (right to buy)
2023-05-01−474→ 33,220 totalExercise: $20.00From: 2019-05-03Exp: 2029-04-03→ Common Stock (474 underlying) - Exercise/Conversion
Option (right to buy)
2023-05-01−2,584→ 18,720 totalExercise: $4.73From: 2021-04-04Exp: 2027-11-30→ Common Stock (2,584 underlying)
Footnotes (3)
- [F1]The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 20, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- [F2]This transaction was executed in multiple trades at price ranging from $43.99 to $45.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]All of the shares subject to the option are fully vested and exercisable as of the date hereof.
Documents
Issuer
Silk Road Medical Inc
CIK 0001397702
Entity typeother
Related Parties
1- filerCIK 0001770191
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 6:39 PM ET
- Size
- 25.1 KB